<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="677">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 11, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003816</url>
  </required_header>
  <id_info>
    <org_study_id>RP 98-15</org_study_id>
    <secondary_id>RP 98-15</secondary_id>
    <nct_id>NCT00003816</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer</brief_title>
  <official_title>Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell&#xD;
      helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune&#xD;
      system from rejecting the donor's stem cells. When the healthy stem cells from a donor are&#xD;
      infused into the patient they may help the patient's bone marrow make stem cells, red blood&#xD;
      cells, white blood cells, and platelets. It is not yet known which combination chemotherapy&#xD;
      regimen is most effective when given before a donor stem cell transplant in treating aplastic&#xD;
      anemia or hematologic cancer.&#xD;
&#xD;
      PURPOSE: This phase II/III trial is studying different combination chemotherapy regimens to&#xD;
      compare how well they work when given before donor stem cell transplant in treating patients&#xD;
      with aplastic anemia or hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the morbidity, mortality, and overall outcome of patients with severe aplastic&#xD;
           anemia or hematologic malignancy treated with standard vs novel conditioning regimens&#xD;
           followed by allogeneic stem cell transplantation.&#xD;
&#xD;
        -  Examine the influence of donor histocompatibility on outcome by comparing&#xD;
           matched/related, mismatched/related (with or without T-cell depletion), and&#xD;
           matched/unrelated transplants with stratification for type of preparative regimen.&#xD;
&#xD;
        -  Ensure that patients with uncommon diagnoses will be treated in a uniform fashion with&#xD;
           the best therapy available.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to risk of relapse (standard-risk: acute leukemia&#xD;
      in first complete remission, chronic myelogenous leukemia in first chronic phase, lymphoma in&#xD;
      sensitive first relapse or second remission, primary or untreated myelodysplastic syndromes,&#xD;
      or untreated severe aplastic anemia vs high-risk: all others).&#xD;
&#xD;
      Patients are assigned to one of the following conditioning regimens based on diagnosis, risk&#xD;
      of relapse, and donor relatedness:&#xD;
&#xD;
        -  Regimen 1: Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and&#xD;
           cyclophosphamide IV over 2 hours on days -3 and -2.&#xD;
&#xD;
        -  Regimen 2: Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and&#xD;
           anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.&#xD;
&#xD;
        -  Regimen 3: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and&#xD;
           total-body irradiation (TBI) twice daily on days -3 to -1.&#xD;
&#xD;
        -  Regimen 4: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and&#xD;
           melphalan IV over 1 hour on days -3 and -2.&#xD;
&#xD;
        -  Regimen 5: Patients receive etoposide IV over 26 hours beginning on day -5,&#xD;
           cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.&#xD;
&#xD;
        -  Regimen 6: Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24&#xD;
           hours, and thiotepa IV over 24 hours on days -7 to -4.&#xD;
&#xD;
        -  Regimen 7: Patients receive fludarabine IV over 30 minutes on days -5 to -1 and&#xD;
           anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.&#xD;
&#xD;
        -  Regimen 8: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI&#xD;
           twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3&#xD;
           to -1.&#xD;
&#xD;
        -  Regimen 9: Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte&#xD;
           globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days&#xD;
           -3 and -2.&#xD;
&#xD;
      All patients then receive donor stem cell infusions on day 0. Some patients may undergo&#xD;
      involved-field radiotherapy 4-8 weeks after transplant.&#xD;
&#xD;
      Patients will be taken off study after a minimum of 4 years of follow up.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 405 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 1998</start_date>
  <completion_date type="Actual">July 12, 2019</completion_date>
  <primary_completion_date type="Actual">July 12, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity of allogeneic stem cell transplant</measure>
    <time_frame>day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of donor histocompatibility on outcome</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Nonmalignant Neoplasm</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 7</arm_group_label>
    <arm_group_label>Regimen 8</arm_group_label>
    <arm_group_label>Regimen 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 5</arm_group_label>
    <arm_group_label>Regimen 6</arm_group_label>
    <arm_group_label>Regimen 8</arm_group_label>
    <arm_group_label>Regimen 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 4</arm_group_label>
    <arm_group_label>Regimen 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Given twice daily for 3 days</description>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 5</arm_group_label>
    <arm_group_label>Regimen 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Severe aplastic anemia as defined by either of the following:&#xD;
&#xD;
                    -  Marrow cellularity (&lt; 25% [or 25-50% cellularity with &lt; 30% of remaining&#xD;
                       cells hematopoietic in origin])&#xD;
&#xD;
                    -  At least 2 of the following abnormal peripheral blood counts:&#xD;
&#xD;
                         -  Reticulocyte count &lt; 1% (corrected for hematocrit)&#xD;
&#xD;
                         -  Platelet count &lt; 20,000/mm^3&#xD;
&#xD;
                         -  Neutrophil count &lt; 500/mm^3&#xD;
&#xD;
               -  Histologically confirmed hematologic malignancy, including any of the following:&#xD;
&#xD;
                    -  Acute leukemia&#xD;
&#xD;
                         -  Resistant or recurrent disease after combination chemotherapy with at&#xD;
                            least one standard regimen OR in first remission and at high risk of&#xD;
                            relapse&#xD;
&#xD;
                         -  Acute myeloid leukemia (AML) (antecedent myelodysplastic syndromes&#xD;
                            [MDS], secondary AML, or high-risk cytogenetic abnormalities)&#xD;
&#xD;
                         -  Acute lymphoblastic leukemia (ALL) (high-risk cytogenetic&#xD;
                            abnormalities)&#xD;
&#xD;
                    -  Chronic myeloid leukemia (CML)&#xD;
&#xD;
                         -  Chronic phase, accelerated phase, or blast phase&#xD;
&#xD;
                    -  Myeloproliferative disorders or MDS, including any of the following:&#xD;
&#xD;
                         -  Myelofibrosis&#xD;
&#xD;
                         -  Polycythemia vera*&#xD;
&#xD;
                         -  Essential thrombocythemia*&#xD;
&#xD;
                         -  Refractory anemia&#xD;
&#xD;
                         -  Refractory anemia with excess blasts&#xD;
&#xD;
                         -  Refractory anemia with excess blasts in transformation&#xD;
&#xD;
                         -  Chronic myelomonocytic leukemia NOTE: * Only if transformed to AML or&#xD;
                            MDS&#xD;
&#xD;
                    -  Lymphoproliferative disease&#xD;
&#xD;
                         -  Recurrent or persistent, symptomatic disease after first-line&#xD;
                            chemotherapy, including any of the following:&#xD;
&#xD;
                              -  Chronic lymphocytic leukemia (CLL) (≥ 20% marrow involvement)&#xD;
&#xD;
                              -  Waldenstrom macroglobulinemia&#xD;
&#xD;
                              -  Low-grade non-Hodgkin lymphoma&#xD;
&#xD;
                    -  Intermediate or high-grade non-Hodgkin lymphoma, meeting 1 of the following&#xD;
                       criteria:&#xD;
&#xD;
                         -  Resistant or recurrent disease after combination chemotherapy with one&#xD;
                            standard regimen&#xD;
&#xD;
                         -  Lymphoblastic lymphoma or small noncleaved cell lymphoma in first&#xD;
                            remission and at high risk of relapse&#xD;
&#xD;
                         -  CNS disease&#xD;
&#xD;
                         -  Bone marrow disease and LDH greater than 300&#xD;
&#xD;
               -  Solid tumor that would otherwise be treated on RPCI-DS-9115 (or equivalent&#xD;
                  autologous stem transplant protocol) AND has a syngeneic donor&#xD;
&#xD;
          -  Autologous bone marrow transplant not possible (or desirable) due to 1 of the&#xD;
             following:&#xD;
&#xD;
               -  History of marrow tumor&#xD;
&#xD;
               -  Inadequate marrow dose&#xD;
&#xD;
               -  Abnormal marrow histology or function prior to storage&#xD;
&#xD;
               -  Thrombocytopenia or leukopenia&#xD;
&#xD;
               -  Marrow cellularity &lt; 20%&#xD;
&#xD;
          -  Histocompatible donor identified&#xD;
&#xD;
               -  Well-matched donor, as defined by 1 of the following:&#xD;
&#xD;
                    -  Family member matched for 5 or 6 HLA specificities (A, B, DR)*&#xD;
&#xD;
                    -  Unrelated donor meeting compatibility criteria of the National Marrow Donor&#xD;
                       Program (matched for HLA A, B, and DRB1 antigens)*&#xD;
&#xD;
                    -  Identical twin sibling&#xD;
&#xD;
               -  If a compatible cord blood donor is identified and there is no suitable unrelated&#xD;
                  donor available, patient may receive cord blood transplant NOTE: *Patients ≤ 25&#xD;
                  years of age may be singly mismatched at the A or B loci&#xD;
&#xD;
        NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.&#xD;
        The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology&#xD;
        of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
        terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  4 to 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin &lt; 3 times normal (unless due to disease)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 3 times normal (unless due to disease)&#xD;
&#xD;
          -  SGOT &lt; 3 times normal (unless due to disease)&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No severe hepatic disease that would preclude study participation&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No severe renal disease that would preclude study participation&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac ventricular ejection fraction ≥ 50% by MUGA or echocardiogram&#xD;
&#xD;
          -  No uncontrolled or severe cardiovascular disease (e.g., myocardial infarction,&#xD;
             congestive heart failure, symptomatic angina, life threatening arrhythmia, or&#xD;
             hypertension within the past 6 months)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO or DLVA ≥ 50% predicted (corrected for hemoglobin or alveolar ventilation)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No serious concurrent medical or psychiatric illness&#xD;
&#xD;
          -  No other serious organ dysfunction (unless due to underlying disease), including the&#xD;
             following:&#xD;
&#xD;
               -  Uncontrolled bacterial, viral, or fungal infection&#xD;
&#xD;
               -  Uncontrolled peptic ulcer disease&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Cytomegalovirus status known&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Pretransplant cytoreductive chemotherapy allowed for patients with relapsed or&#xD;
             refractory disease&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not eligible for total-body irradiation if prior radiotherapy exceeded the following&#xD;
             limits:&#xD;
&#xD;
               -  Mediastinum: 3,600 cGy&#xD;
&#xD;
               -  Heart: 3,600 cGy&#xD;
&#xD;
               -  Whole lungs: 1,200 cGy&#xD;
&#xD;
               -  Small bowel: 3,600 cGy&#xD;
&#xD;
               -  Kidneys: 1,200 cGy&#xD;
&#xD;
               -  Whole liver: 1,600 cGy&#xD;
&#xD;
               -  Cranial spinal: 3,600 cGy&#xD;
&#xD;
               -  Brain: 4,000 cGy&#xD;
&#xD;
               -  Retina: 4,000 cGy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip L. McCarthy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

